KKR invests $200m in India's Gland
This article was originally published in Scrip
Executive Summary
Niche verticals such as injectables continue to attract private equity (PE) interest in India, with the global investment firm, KKR, acquiring a minority stake in Gland Pharma for about $200m – the largest PE investment in a local pharmaceutical firm in recent times.
You may also be interested in...
Fosun Pitches for India's Gland
Shanghai Fosun Pharmaceutical Group Co. Ltd. has confirmed it interest in the Indian injectables firm, Gland Pharma Ltd., underscoring how differentiated niche plays continue to attract buyer interest.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet